Regadenoson (hydrate)

Regadenoson hydrate (NSC 169186) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson hydrate also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of agents to the human CNS[1][2].

Product Specifications

CAS Number

[875148-45-1]

Product Name Alternative

CVT-3146 (hydrate)

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

Adenosine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/regadenoson-hydrate.html

Smiles

OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(N=C2)C(N)=NC(N4C=C(C=N4)C(NC)=O)=N3)O1.O

Molecular Formula

C15H20N8O6

Molecular Weight

408.37

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Trochu JN, et al. Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol. 2003 Jan;41 (1) :132-9. |[2]Jackson S, et al. The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. J Neurooncol. 2016 Feb;126 (3) :433-9.